Abstract
With regard to the use of rituximab for patients with steroid-dependent nephrotic syndrome and frequently relapsing nephrotic syndrome, not only has the regimen not been clinically verified but also there is a lack of health economics evidence. Therefore, we conducted a prospective clinical study on 30 patients before (with steroids and immunosuppressants) and after introducing rituximab therapy. Relapse rates and total invoiced medical expenses were selected as the primary endpoints for treatment effectiveness and treatment costs, respectively. As secondary endpoints, cost-effectiveness was compared before and after administering rituximab in relation to previous pharmacotherapy. The observation period was 24 months before and after the initiation of rituximab. We showed that there was a statistically significant improvement in the relapse rate from a mean of 4.30 events before administration to a mean of 0.27 events after administration and that there was a significantly better prognosis in the cumulative avoidance of relapse rate by Kaplan–Meier analysis (p < 0.01). Finally, the total medical costs decreased from 2,923 USD to 1,280 USD per month, and the pre–post cost-effectiveness was confirmed as dominant. We, therefore, conclude that treatment with rituximab was possibly superior to previous pharmacological treatments from a health economics perspective.
Highlights
With regard to the use of rituximab for patients with steroid-dependent nephrotic syndrome and frequently relapsing nephrotic syndrome, has the regimen not been clinically verified and there is a lack of health economics evidence
Since 2004, there have been some reports showing that administering rituximab to patients with refractory nephrotic syndrome can lead to remission and reduce or eliminate
While the use of rituximab in nephrological indications is increasing for refractory nephrotic syndrome, few reports have evaluated the medical economics of rituximab for either steroid-dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)
Summary
With regard to the use of rituximab for patients with steroid-dependent nephrotic syndrome and frequently relapsing nephrotic syndrome, has the regimen not been clinically verified and there is a lack of health economics evidence. We conducted a prospective clinical study on 30 patients before (with steroids and immunosuppressants) and after introducing rituximab therapy. Since 2004, there have been some reports showing that administering rituximab to patients with refractory nephrotic syndrome can lead to remission and reduce or eliminate www.nature.com/scientificreports/. While the use of rituximab in nephrological indications is increasing for refractory nephrotic syndrome, few reports have evaluated the medical economics of rituximab for either steroid-dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS). It is difficult to draw any robust conclusions regarding the optimal dosing schedule of rituximab
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
